Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5887
    -0.0018 (-0.31%)
     
  • NZD/EUR

    0.5525
    -0.0020 (-0.35%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    83.17
    +0.44 (+0.53%)
     
  • GOLD

    2,411.80
    +13.80 (+0.58%)
     
  • NASDAQ

    17,002.38
    -391.94 (-2.25%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,914.10
    +138.72 (+0.37%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    90.9930
    -0.2610 (-0.29%)
     

Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations

Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations

Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.